COMMUNIQUÉS West-GlobeNewswire

CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée
25/09/2026
CROSSJECT publie ses résultats du premier semestre 2026 et présente une structure financière profondément renforcée Trésorerie de 12,3 M€ au 30 juin 2026, multipliée par 2,4 par rapport au 31 décembre 2025 (5,1 M€), [...]
CROSSJECT Reports Its First-Half 2026 Results and Presents a Significantly Strengthened Financial Structure
25/09/2026
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity [...]
CROSSJECT structure sa gouvernance pour la phase de déploiement industriel et commercial
25/09/2026
Le Directoire est élargi à cinq membres : Olivier LACOMBE, Didier MORIN et Lionel SELTZ rejoignent Patrick ALEXANDRE et Isabelle LIEBSCHUTZ Une direction qui couvre l’intégralité de la chaîne de valeur : développement [...]
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
25/09/2026
The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz A leadership team covering the entire value chain: pharmaceutical [...]
Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
25/09/2026
LONDON and PHILADELPHIA, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces the [...]
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
25/09/2026
Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026 BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Neuraxpharm Group [...]
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
25/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric [...]
IBA va coordonner LIFEDESTINY, un nouveau projet européen pour l'élimination durable des PFAS
25/09/2026
Louvain ‑ la ‑ Neuve, Belgique, le 25 septembre 2026, 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélérateurs de particules, annonce ce jour qu'elle coordonnera LIFEDESTINY [...]
IBA to coordinate LIFEDESTINY, a new European LIFE project to advance sustainable PFAS remediation
25/09/2026
Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new [...]
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
25/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized [...]
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
24/09/2026
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 -- CAMBRIDGE [...]
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
24/09/2026
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics ( [...]
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
24/09/2026
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by [...]
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
24/09/2026
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
24/09/2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026 [...]
Buckingham Psychiatry Welcomes Psychologist Dr. Sophie Buinewicz
24/09/2026
The Bucks County-Based Mental Health Practice Introduces a Licensed Clinical Psychologist to Its Team DOYLESTOWN, Pa. and LAMBERTVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Buckingham Psychiatry, serving patients in [...]
Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
24/09/2026
DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
NANOBIOTIX fait le point sur ses activités et ses résultats financiers du premier semestre 2026
24/09/2026
Résultats préliminaires prometteurs issus de l’analyse complète des cohortes dans les parties escalade et expansion de dose d’une étude achevée de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints d’un [...]
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
24/09/2026
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non [...]

Pages